{"id":"spd503-2-mg","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by activating dopamine receptors in the brain, which helps to improve symptoms of certain conditions.","oneSentence":"SPD503 is a dopamine receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:46.891Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"}]},"trialDetails":[{"nctId":"NCT04085172","phase":"PHASE4","title":"A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2019-09-18","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":396},{"nctId":"NCT01500694","phase":"PHASE3","title":"Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe","status":"COMPLETED","sponsor":"Shire","startDate":"2012-03-20","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":215},{"nctId":"NCT00152009","phase":"PHASE3","title":"Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17","status":"COMPLETED","sponsor":"Shire","startDate":"2003-01-29","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":345},{"nctId":"NCT01470469","phase":"PHASE2","title":"SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)","status":"COMPLETED","sponsor":"Shire","startDate":"2012-01-04","conditions":"Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social","enrollment":83},{"nctId":"NCT00150618","phase":"PHASE3","title":"Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17","status":"COMPLETED","sponsor":"Shire","startDate":"2004-03-30","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":324}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SPD503 (2 mg)","genericName":"SPD503 (2 mg)","companyName":"Shire","companyId":"shire","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SPD503 is a small molecule with the synonym MG-S-2525, used in clinical trials for various conditions including Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder (ADHD), Generalized Anxiety Disorder (GAD), and anxiety-related phobias. It has been studied in doses of 1 mg, 2 mg, and 3 mg in clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}